Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 713

1.

Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.

Raichlin E, Khalpey Z, Kremers W, Frantz RP, Rodeheffer RJ, Clavell AL, Edwards BS, Kushwaha SS.

Transplantation. 2007 Aug 27;84(4):467-74.

PMID:
17713429
2.

Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity.

Kushwaha SS, Khalpey Z, Frantz RP, Rodeheffer RJ, Clavell AL, Daly RC, McGregor CG, Edwards BS.

J Heart Lung Transplant. 2005 Dec;24(12):2129-36.

PMID:
16364861
3.

Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.

Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF; Sirolimus CONVERT Trial Study Group..

Transplantation. 2009 Jan 27;87(2):233-42. doi: 10.1097/TP.0b013e3181927a41.

PMID:
19155978
4.

Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation.

Stephany BR, Augustine JJ, Krishnamurthi V, Goldfarb DA, Flechner SM, Braun WE, Hricik DE, Dennis VW, Poggio ED.

Transplantation. 2006 Aug 15;82(3):368-74.

PMID:
16906035
5.

Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease.

Stephany BR, Boumitri M, Budev M, Alao B, Poggio ED.

J Heart Lung Transplant. 2009 Jun;28(6):564-71. doi: 10.1016/j.healun.2009.03.010.

PMID:
19481016
6.

Evolution of glomerular filtration rate, renal injury markers, anemia, and angiotensin blockers use after change from calcineurin inhibitors to sirolimus in transplant patients with neoplasia versus chronic allograft nephropathy.

Luna E, Cerezo I, Macias R, Villa J, Martinez C, Cubero J, Martinez R, Ferreira F, García C.

Transplant Proc. 2011 Jul-Aug;43(6):2187-90. doi: 10.1016/j.transproceed.2011.06.055.

PMID:
21839229
7.

Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.

Uslu A, Töz H, Sen S, Alkan FT, Nart A, Aykas A, Doğan M, Postaci H, Sahin T, Simşek C.

Transplant Proc. 2009 Mar;41(2):756-63. doi: 10.1016/j.transproceed.2009.01.044.

PMID:
19328973
8.

Conversion from calcineurin inhibitors to sirolimus in kidney transplant recipients: a retrospective cohort study.

Cardinal H, Froidure A, Dandavino R, Daloze P, Hébert MJ, Colette S, Boucher A.

Transplant Proc. 2009 Oct;41(8):3308-10. doi: 10.1016/j.transproceed.2009.08.049.

PMID:
19857737
9.

Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.

Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L.

Nephrol Dial Transplant. 2005 Nov;20(11):2517-23. Epub 2005 Jun 28.

PMID:
15985508
10.

Sirolimus-based immunosuppressive therapy in liver transplant recipient with tacrolimus-related chronic renal insufficiency.

Yang YJ, Chen DZ, Li LX, Kou JT, Lang R, Jin ZK, Han DD, He Q.

Transplant Proc. 2008 Jun;40(5):1541-4. doi: 10.1016/j.transproceed.2008.01.081.

PMID:
18589147
11.

Protocol conversion from a calcineurin inhibitor based therapy to sirolimus.

Oberbauer R.

Transplantation. 2009 Apr 27;87(8 Suppl):S7-10. doi: 10.1097/TP.0b013e3181a0582a.

PMID:
19384186
12.

Conversion to sirolimus in renal transplant recipients: a single-center experience.

Yelken B, Caliskan Y, Ozkan O, Gorgulu N, Yazici H, Turkmen A, Sever MS.

Artif Organs. 2010 Aug;34(8):E230-7. doi: 10.1111/j.1525-1594.2010.01022.x. Epub 2010 Jul 6.

PMID:
20618227
13.

Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients.

Morard I, Dumortier J, Spahr L, Hadengue A, Majno P, Morel P, Mentha G, Giostra E.

Liver Transpl. 2007 May;13(5):658-64.

14.

Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction.

Diekmann F, Budde K, Oppenheimer F, Fritsche L, Neumayer HH, Campistol JM.

Am J Transplant. 2004 Nov;4(11):1869-75.

15.

Improved 24-hour blood pressure control with sirolimus versus calcineurin inhibitor based immunosuppression in renal transplant recipients.

Steigerwalt SP, Brar N, Dhungel A, Butcher D, Steigerwalt S, El-Ghouroury M, Provenzano R.

Transplant Proc. 2009 Dec;41(10):4184-7. doi: 10.1016/j.transproceed.2009.07.109.

PMID:
20005365
16.

A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.

Watson CJ, Gimson AE, Alexander GJ, Allison ME, Gibbs P, Smith JC, Palmer CR, Bradley JA.

Liver Transpl. 2007 Dec;13(12):1694-702.

17.

Usefulness of sirolimus as rescue therapy in heart transplant recipients with renal failure: analysis of the Spanish Multicenter Observational Study (RAPACOR).

Delgado JF, Crespo MG, Manito N, Camprecios M, Rábago G, Lage E, Arizón JM, Roig E.

Transplant Proc. 2009 Nov;41(9):3835-7. doi: 10.1016/j.transproceed.2009.06.236.

PMID:
19917397
18.

Conversion to sirolimus with calcineurin inhibitor elimination vs. dose minimization and renal outcome in heart and lung transplant recipients.

Demirjian S, Stephany B, Abu Romeh IS, Boumitri M, Yamani MH, Poggio ED.

Clin Transplant. 2009 Jun-Jul;23(3):351-60. doi: 10.1111/j.1399-0012.2009.00963.x. Epub 2009 Feb 5.

PMID:
19208105
19.

Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus.

Larson TS, Dean PG, Stegall MD, Griffin MD, Textor SC, Schwab TR, Gloor JM, Cosio FG, Lund WJ, Kremers WK, Nyberg SL, Ishitani MB, Prieto M, Velosa JA.

Am J Transplant. 2006 Mar;6(3):514-22.

20.

Calcineurin inhibitor minimization using sirolimus leads to improved renal function in pediatric heart transplant recipients.

Chinnock TJ, Shankel T, Deming D, Cutler D, Sahney S, Fitts J, Chinnock RE.

Pediatr Transplant. 2011 Nov;15(7):746-9. doi: 10.1111/j.1399-3046.2011.01566.x. Epub 2011 Aug 23.

PMID:
21883751

Supplemental Content

Support Center